# Evidence-Based Recommendations on the Use of Immunotherapies and Monoclonal Antibodies in the Treatment of Male Reproductive Cancers

## TL;DR

This review summarizes the latest evidence on immunotherapies and monoclonal antibodies for treating male reproductive cancers like prostate, testicular, and penile cancers.

## Contribution

The paper offers evidence-based guidance on using immunotherapies and monoclonal antibodies for male reproductive cancers.

## Key findings

- Immunotherapies and monoclonal antibodies show promise for treating resistant cases of male reproductive cancers.
- These therapies target immune checkpoints and tumor-specific antigens to improve outcomes.
- The review highlights current treatments and future directions for optimizing patient care.

## Abstract

The incidence of male reproductive cancers, including prostate, testicular, and penile cancers, has risen in recent years, raising important health concerns. Prostate cancer is the second leading cause of cancer-related mortality in men, while penile cancer, though rare, typically affects men over 60. Testicular cancer, with a lifetime risk of about 0.4% in men, is most common among adolescents and young adults, decreasing sharply after the age of 40. Traditional treatments include chemotherapy, radiation, surgery, and combinations thereof, but advancements in immunotherapy and monoclonal antibodies are showing promising results, particularly for genitourinary cancers. These therapies, targeting immune checkpoints and tumor-specific antigens, are gaining traction as effective alternatives for resistant cases. This review provides evidence-based recommendations on current and emerging immunotherapy and monoclonal antibody treatments for male reproductive cancers, highlighting future directions to optimize patient outcomes.